Sonoma Pharmaceuticals, Inc.
SNOA
$2.97
$0.051.71%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.19% | 13.51% | 11.81% | -0.13% | -4.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.19% | 13.51% | 11.81% | -0.13% | -4.05% |
| Cost of Revenue | 10.43% | 14.80% | 1.24% | -5.18% | -4.82% |
| Gross Profit | 15.17% | 11.29% | 34.17% | 9.29% | -2.71% |
| SG&A Expenses | -2.83% | 5.28% | -9.06% | -13.81% | -14.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.22% | 10.07% | 1.58% | -1.90% | -2.26% |
| Operating Income | 21.08% | -0.54% | 21.24% | 6.42% | -2.93% |
| Income Before Tax | 42.22% | 26.86% | 38.59% | 19.87% | 2.93% |
| Income Tax Expenses | 380.61% | 128.57% | -200.00% | 43.33% | -512.50% |
| Earnings from Continuing Operations | 28.50% | 26.16% | 40.06% | 19.75% | 6.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.50% | 26.16% | 40.06% | 19.75% | 6.13% |
| EBIT | 21.08% | -0.54% | 21.24% | 6.42% | -2.93% |
| EBITDA | 21.06% | -1.05% | 21.94% | 7.25% | -1.87% |
| EPS Basic | 78.95% | 79.41% | 83.70% | 67.43% | 53.15% |
| Normalized Basic EPS | 82.09% | 79.23% | 83.02% | 68.63% | 53.45% |
| EPS Diluted | 78.95% | 79.41% | 83.70% | 67.43% | 53.15% |
| Normalized Diluted EPS | 82.09% | 79.23% | 83.02% | 68.63% | 53.45% |
| Average Basic Shares Outstanding | 172.99% | 225.67% | 266.21% | 214.41% | 167.80% |
| Average Diluted Shares Outstanding | 172.99% | 225.67% | 266.21% | 214.41% | 167.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |